CEVR Researcher and Author Dan Ollendorf Discusses QALYs, Reducing Prescription Drug Prices Using Value, and HTAs

Dr. Dan Ollendorf of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts University Medical Center recently published a book on drug prices with two other CEVR co-authors. He discusses his research with Managed Healthcare Executive’s Peter Wehrwein. One solution to rein in drug prices is the use of a value-based system. Ollendorf also discusses how a government agency or health technology assessment (HTA) in the United States could set prices and the benefits of the quality-adjusted life years (QALY) metric.

Dr. Ollendorf remarks, “Now, another thing that we often say is that while the QALY and cost-effectiveness analysis is an input into decision-making, but it’s only one. There are other important aspects of new treatments that we should be considered. Is this the first new treatment that’s become available for very severe disease in a very long time, for example? Is there a significant burden of disease?” Read more here.

(Source: Peter Wehrwein, Managed Healthcare Executive, 5/28/21)